Background & Aims: Our understanding of the intestinotropic actions of glucagon-like peptide-2 (GLP-2) 1-33 is based on pharmacologic studies involving exogenous administration. However, the physiologic role of GLP-2 in mucosal growth and adaptation to nutritional stimulation remains poorly understood. Methods: The properties of GLP-2 3-33 , a GLP-2 1-33 metabolite, were determined in baby-hamster kidney cells transfected with the mouse GLP-2 receptor complementary DNA and in isolated murine intestinal muscle strips. To investigate the role of endogenous GLP-2 1-33 in gut adaptation, GLP-2 3-33 was administered to mice that were re-fed for 24 hours after 24 hours of fasting, and the small intestine was analyzed. GLP-2 3-33 also was injected into rats for analysis of circulating GLP-2 1-33 levels. Results: GLP-2 3-33 antagonized the actions of GLP-2 1-33 in vitro and ex vivo. Fasting mice exhibited small intestinal atrophy (37% ؎ 1% decrease in small intestinal weight, 19% ؎ 2% decrease in crypt-villus height, and 99% ؎ 35% increase in villus apoptosis, P < .05-.01). Adaptive growth in re-fed mice restored all these parameters, as well as crypt-cell proliferation, to normal control levels (P < .05 vs. fasting); these adaptive changes were prevented partially or completely by co-administration of GLP-2 3-33 to refeeding mice (by 32% ؎ 19% to 103% ؎ 15%, P < .05-.01 vs re-fed mice). Exogenous GLP-2 3-33 did not affect endogenous GLP-2 1-33 levels. Conclusions: These data show that endogenous GLP-2 regulates the intestinotropic response in re-fed mice through modulation of crypt-cell proliferation and villus apoptosis. GLP-2 is therefore a physiologic regulator of the dynamic adaptation of the gut mucosal epithelium in response to luminal nutrients.
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T he small intestine exhibits a remarkable capacity to adapt to changes in nutritional status whereby the absence of luminal nutrients induces mucosal atrophy, and subsequent reintroduction of enteral nutrition results in adaptive regrowth of the mucosal epithelium. 1, 2 Although most species exhibit some degree of gut adaptation in response to a nutrient challenge, 3, 4 the murine fasting and refeeding model shows exceptional plasticity within a very short time frame. Mice that undergo fasting for 24 hours exhibit significant atrophy of the gut, whereas refeeding for a subsequent 24 hours restores the gut epithelium toward normal. 1 This atrophy and subsequent regrowth are associated with decreased and increased crypt-villus height, respectively. A number of different hormones have been implicated in regulating gut growth including insulin-like growth factor-1, growth hormone, keratinocyte growth factor, and epidermal growth factor. 5 More recently, interest has focused on the actions of the intestinal hormone glucagonlike peptide-2 (GLP-2) not only because of its potent intestinotropic effects, but also because of the pleiotropic effects of GLP-2 on nutrient absorption, gut permeability, and mucosal cytoprotection. 6, 7 GLP-2 is a 33 amino-acid peptide secreted by the enteroendocrine L cell of the intestinal epithelium. 8 -10 Exogenous administration of GLP-2 to normal rodents, as well as to rodents with intestinal damage or inflammation, stimulates intestinal epithelial growth through increased proliferation in the crypts and decreased apoptosis in the villus tips. 6, 7, [11] [12] [13] [14] Exogenous GLP-2 administration also increases nutrient absorption, decreases intestinal permeability, and inhibits gastrointestinal motility. [15] [16] [17] [18] [19] Consistent with these findings, preclinical studies in patients with short-bowel syndrome showed that administration of GLP-2 increased their capacity to absorb enteral nutrients. 20 Circulating levels of GLP-2 are decreased in the fasting state. GLP-2 secretion from the L cell is stimulated by ingestion of nutrients, specifically carbohydrates and fat. 9, 10, 21 The plasma half-life of exogenously administered GLP-2 is approximately 7 minutes in humans, 22 caused in part by renal clearance and enzymatic inactivation of the full-length peptide by the ubiquitous enzyme dipeptidylpeptidase-IV (DP-IV). DP-IV cleaves 2 amino acids off the N-terminal end of GLP-2 , liberating the metabolite, GLP-2 . 23, 24 Although GLP-2 has been shown to be inactive biologically with respect to the stimulation of intestinal growth, 23, 25 GLP-2 has been shown to function both as a weak partial agonist and as an antagonist when given together with exogenous GLP-2 1-33 in mice. 26 Our current understanding of GLP-2 as an intestinotropic hormone has been based largely on pharmacologic studies in which the peptide has been administered exogenously, leading to supraphysiologic levels of circulating GLP-2. In contrast, the lack of well-characterized GLP-2-receptor (GLP-2R) antagonists has constrained our understanding of the physiologic role of endogenous GLP-2 under different experimental conditions. In the current study we cloned the mouse GLP-2R complementary DNA (cDNA) and used this reagent, as well as an ex vivo mouse muscle strip preparation, to show that GLP-2 3-33 is a murine GLP-2R antagonist. Furthermore, we used GLP-2 to test the hypothesis that endogenous GLP-2 1-33 is required for nutrient regulation of intestinal mucosal growth.
Materials and Methods

Peptides
Synthetic rat (r) GLP-2 3-33 and rGLP-2 5-33 were provided by NPS-Allelix Biopharmaceuticals (Mississauga, Ontario, Canada). Human (h) GLP-2 3-33 was purchased from Peptidec Technologies, Ltd. (Pierrefonds, Quebec, Canada), and the degradation-resistant analog h(Gly 2 )-GLP-2 1-33 was obtained from American Peptide Company (Sunnyvale, CA). The various molecular forms of GLP-2 used in this study have a high sequence homology, as shown in Table 1 . The authenticity and integrity of these peptides were verified by mass spectrometry (data not shown, University of Toronto, Toronto, Ontario, Canada). Synthetic GLP-1 7-36NH2 was purchased from Bachem California, Inc. (Torrance, CA) and rat albumin was purchased from Sigma Chemical Co. (St. Louis, MO).
Animals
Six-week-old female CD1 mice and 400 -500 g adult male Wistar rats were obtained from Charles River Canada (St. Constant, Quebec, Canada). All animal protocols were approved by the Animal Care Committee of the University of Toronto.
Reverse-Transcription Polymerase Chain
Reaction Amplification of Mouse GLP-2R mRNA and cDNA Cloning Total cellular RNA was extracted from colon and jejunum of mice (C57BL/6) with Trizol reagent (Invitrogen Life Technologies, Inc, Burlington, Ontario, Canada). A total of 10 -12 g of RNA from each tissue was treated with deoxyribonuclease I and reverse transcribed using random hexamers and the Superscript II first-strand synthesis kit (Invitrogen Life Technologies, Inc.), according to the manufacturer's instructions. To control for contamination, reactions also were performed in the absence of Superscript II. First-strand cDNAs were treated with ribonuclease H to remove RNA, and polymerase chain reactions (PCRs) were performed using Taq DNA polymerase (MBI Fermentas, Burlington, Ontario, Canada) with first-strand cDNAs as templates. Sense (5=-AGG-GGTACCGCCACCATGCGTCGGCTCTGGGGCCCT-3= ) and antisense (5=-TTAGATCTCACTCTCTTCCAGAATCTC-3=) primers (ACTG, Toronto, Ontario, Canada) were used for 45 cycles of PCR performed at 95°C for 1 minute, 65°C for 2 minutes, and 72°C for 1.5 minutes. The sense primer was designed to insert a Kpn I site and an optimized Kozak sequence upstream of the initiator start codon. To verify specificity of the PCR product, aliquots from each reaction were resolved by gel electrophoresis and transferred to a nylon membrane (Schleicher & Schuell Bioscience, Keene, NH). The identity of the 1.6-kb full-length mouse (m) GLP-2R cDNA was confirmed after hybridization to a [ 32 P]-labeled internal cDNA fragment of the rGLP-2R, as described previously. 25, 27 Aliquots of colon and jejunum PCR reactions were purified on GFX PCR columns (Amersham Biosciences, Piscataway, NJ) and ligated to the pCR4 vector using the Topo TA cloning kit (Invitrogen Life Technologies). GLP-2R cDNA clones from both jejunum and colon were isolated and fulllength mGLP-2R cDNA was sequenced (Core Molecular Biology Facility, York University, Ontario, Canada), and ligated into the Kpn I and Eco RI sites of pcDNA 3.1 (Invitrogen Life Technologies, Inc.) for expression studies. Because the GLP-2R cDNA sequences from mouse jejunum and colon were identical, further studies were performed using the GLP-2 receptor cDNA cloned from the jejunum.
In Vitro Studies
Baby-hamster kidney (BHK) fibroblasts were transfected transiently with the mouse GLP-2R cDNA (BHKmGLP-2R) using FuGene (Roche Diagnostics, Quebec, Canada). Cells were plated in standard tissue culture dishes and grown in Dulbecco's modified Eagle medium with high glucose (4.5 g/L) and 10% fetal bovine serum at 37°C with 5% CO 2 and constant humidity. Twenty-four hours after transfection, GLP-2R activation was assessed by measuring adenosine 3=,5=-cyclic monophosphate (cAMP) production, as previously described. 25, 28 In brief, all treatments were prepared in Dulbecco's modified Eagle medium containing 100 mol/L 3-isobutyl-1-methylxanthine. Cells were preincubated for 5 minutes at 37°C in medium containing vehicle or rGLP-2 before the addition of media alone (basal), rGLP-2 , and/or h(Gly 2 )-GLP-2 at the indicated concentrations for 10 minutes. The reaction was terminated by addition of 1 mL of anhydrous ethyl alcohol at Ϫ20°C (final concentration, 77% EtOH) and plates were allowed to sit at Ϫ20°C for 24 hours. The extracts were collected and cAMP levels were determined by using a cAMP radioimmunoassay kit (Biomedical Technologies, Stoughton, MA). cAMP levels were normalized to total cellular protein, as determined by using the Bradford assay (Bio-Rad Laboratories, Hercules, CA). Basal cAMP levels were .33 Ϯ .01 pmole/g protein, and 100 mol/L forskolin (positive control) increased cAMP production by 381% Ϯ 50% (P Ͻ .01).
Ex Vivo Studies
One-centimeter sections of midjejunum (collected between 16 -24 cm distal to the pyloric sphincter) were excised from female CD1 mice that were euthanized by cervical dislocation. Muscle layers then were stripped from the mucosa and analyzed for GLP-2R mRNA transcripts by reverse-transcription (RT)-PCR, as described below, or collected in ice-cold Hanks' balanced salt solution. All treatments were prepared in Dulbecco's modified Eagle medium with low glucose (1.0 g/L) containing 50 mol/L 3-isobutyl-1-methylxanthine. Each treatment group contained two 1-cm muscle strips and were preincubated for 5 minutes at room temperature in media containing vehicle or GLP-2 3-33 before a 30-minute incubation with media alone (control), GLP-2 , and/or h(Gly 2 )-GLP-2 at the indicated concentrations at 37°C with 5% CO 2 . The reaction was terminated by homogenization of the muscle strips with ethanol at Ϫ20°C, followed by centrifugation to remove the debris. The supernatant then was assayed for cAMP while the pellet was dissolved in 80% formic acid and assayed for protein, as described earlier. Basal cAMP levels for muscle strip experiments were .0169 Ϯ .0013 pmol/g protein.
In Vivo Studies
Mice had free access to water but access to standard chow was determined by their respective treatments. Fasted mice had no access to chow for the 24-hour period before they were killed. Re-fed mice were fasted for 24 ) was administered subcutaneously 24 and 12 hours before death. In re-fed mice, vehicle or peptide administration coincided with the 24-hour refeeding period.
Small intestines were collected from euthanized mice and the weights were determined after gentle removal of the luminal contents and the mesenteric fat. The proximal duodenum (first 5 cm immediately after the pyloric sphincter) was homogenized in 2.4 mL of PBS and stored at Ϫ20°C until assessment of enzymatic activity. A 5-cm distal duodenal section (8 -13 cm distal to the pyloric sphincter) was collected to determine water and protein composition. A 1-cm segment from the proximal jejunum (13-14 cm distal to the pyloric sphincter) was divided into 4 cross-sections, fixed in 10% neutral-buffered formalin, paraffin embedded, and cut into 4-m sections for morphometry and immunohistochemistry. One-centimeter sections from jejunum and ileum (16 -17 cm distal to the pyloric sphincter and 2-3 cm proximal to the cecum, respectively) also were excised, snap-frozen in liquid nitrogen, and stored at Ϫ80°C for RT-PCR.
Morphometry and Immunohistochemistry
Morphometric analysis was performed on cross-sections stained with H&E using a Zeiss microscope with Axio Vision Software (Carl Zeiss Canada, Don Mills, Ontario, Canada). For each mouse, the mean crypt-villus height was obtained from blinded measurements made in all 4 cross-sections, with an average of 28 measurements made for each mouse.
Immunohistochemistry for Ki-67, a marker expressed exclusively during proliferative stages of the cell cycle, 29 was performed using the rat anti-mouse Ki-67 TEC-3 antibody (DAKO, Glostrup, Denmark). In brief, endogenous peroxidase activity was blocked with 3% H 2 O 2 and, after antigen retrieval, nonspecific binding was blocked with Blocking Reagent (Signet, Dedham, MA). The primary antibody was applied at a dilution of 1:150 for 1 hour at room temperature, followed by rabbit biotinylated anti-rat immunoglobulin G antibody (1:200; Vector, Burlingame, CA) for 30 minutes at room temperature. Visualization was performed using Ultra Streptavidin-Horseradish Peroxidase Complex: Level 2 Labeling Reagent (Signet) with 3,3=-diaminobenzidine (Vector), followed by counterstaining with hematoxylin (Sigma Chemical Company). For negative controls, the primary antibody was omitted from the protocol. For each mouse an average of 25 well-oriented and intact half crypts were analyzed. For each half crypt, 20 cells were counted with the cell at the base of the crypt designated as position 0. Proliferation was determined by counting the number of labeled cells relative to total cells for every cell position.
Apoptosis was assessed by detection of DNA fragmentation using an in situ terminal deoxynucleotide transferase-mediated deoxyuridine triphosphate nick-end labeling (TUNEL) assay. Sections were processed with an ApopTag in situ Apoptosis Detection Kit (Intergen, Purchase, NY) according to the manufacturer's instructions. Rat mammary gland tissue provided in the kit was used as a positive control, and terminal deoxynucleotide transferase enzyme was omitted from the reaction mixture for the negative control. Apoptosis initially was determined for the entire length of the crypt-villus axis. However, pilot studies determined that the majority of apoptotic cells resided in the first 30 cell positions from the villus tip (position 0; data not shown). The occurrence and position of apoptotic cells therefore were recorded along the villus axis for the first 30 cells of 50 well-oriented and intact half villi (on average) for each mouse.
Biochemical Analyses
To determine small intestinal composition, tissue samples were weighed (wet weight) and then frozen at Ϫ80°C before being lyophilized and weighed again (dry weight). The H 2 O contribution to total weight was determined by subtracting the dry weight from the wet weight. The dried tissue then was reconstituted in 5 mL of distilled H 2 O and homogenized and the protein content was determined by Bradford assay (Bio-Rad Laboratories).
Frozen duodenal sections were homogenized in 2.4 mL of sodium phosphate buffer, pH 7, at 4°C for determination of maltase, sucrase, and DP-IV activity, as previously described. 15 Activity of all enzymes was expressed per gram of protein, and 1 unit of activity (U) represents 1 mol of substrate hydrolyzed/min at 37°C.
RT-PCR
Total tissue RNA was extracted using the RNeasy kit (Qiagen, Mississauga, Ontario, Canada), with RNase-free DNase-I (Qiagen). Total RNA levels were quantified for each tissue using ultraviolet absorbance at 260 nm. Oligonucleotide primers for semiquantitative RT-PCR are shown in Table 2 . 30 -32 Semiquantitative RT-PCR was performed using the OneStep RT-PCR kit (Qiagen) according to the manufacturer's instructions. Proglucagon RT-PCR conditions were as follows: 50°C for 30 minutes, and 95°C for 15 minutes, followed by 94°C for 1 minute, 67°C for 1 minute, and 72°C for 1 minute for 30 cycles, and then by 72°C for 10 minutes. GLP-2R and RT-PCR conditions were as follows: 50°C for 30 minutes, 95°C for 15 minutes, followed by 94°C for 1 minute, 57.8°C for 1 minute, and 72°C for 1 minute for 29 cycles, and then by 72°C for 10 minutes. The 18S ribosomal RNA RT-PCR conditions were as follows: 50°C for 30 minutes, and 95°C for 15 minutes, followed by 94°C for 1 minute, 60°C for 45 seconds, and 72°C for 1 minute for 19 cycles, and then 72°C for 10 minutes. RT-PCR product sizes were verified on a 1.5% agarose gel electrophoresis stained with ethidium bromide and a parallel reaction with omission of the reverse-transcriptase enzyme was performed to show the absence of contaminating genomic DNA (data not shown). RT-PCR products were quantified by ion-exchange high-performance liquid chromatography (HPLC) analysis. Briefly, HPLC was performed using a Waters Breeze system (Waters Ltd, Mississauga, Ontario, Canada) with a TSK-GEL DNA-NPR column (4.6 mm ϫ 75 mm; TOSOH Bioscience, Montgomeryville, PA). Eluant A (20 mmol/L Tris, pH 9.0) and eluant B (1 mol/L NaCl and 20 mmol/L Tris, pH 9.0) were used for gradient elution, as follows: 53.5% eluant B for 1 minute, then a linear increase to 58.5% eluant B for 2 minutes, followed by another increase to 100% eluant B for .3 minutes, and a purge at 100% eluant B for 1.7 minutes, all at 1 mL/min. Areas of the proglucagon and GLP-2R RT-PCR products (as detected at 254 nm) were normalized to those of the 18S product. Linear RT-PCR amplification was determined using a range of input total RNA concentrations and different cycle numbers (data not shown).
Plasma GLP-2 Levels
Analysis of both GLP-2 1-33 and GLP-2 3-33 was performed using HPLC and radioimmunoassay, as previously described. 21 These studies were performed in rats because extensive analyses using murine samples showed high levels of variation as a consequence of the requirement for pooling of plasma from up to 7 animals to make each n ϭ 1. Briefly, rats were anesthetized lightly by using halothane before receiving a 60 mg/kg intraperitoneal injection of sodium pentobarbital. Blood samples were collected 30 minutes after subcutaneous injection of either PBS (vehicle) or GLP-2 3-33 (1.2 g/kg, equivalent to the 30-ng dose of GLP-2 3-33 administered to mice). Blood samples (7 mL) were collected into 700 L Trasylol (5000 kallikrein inactivating units/mL; Bayer, Inc, Toronto, Ontario, Canada), ethylenediaminetetraacetic acid (1.2 mg/mL), and diprotin-A (.1 mmol/L). Plasma then was separated from red blood cells by centrifugation, followed by extraction of peptides from 2 mL of plasma by addition of 4 mL 1% trifluoroacetic acid (pH adjusted to 2.5 with diethylamine) and collection on a C 18 Sep Pak cartridge (Waters Associates, Bedford, MA). GLP-2 1-33 and GLP-2 3-33 were separated by HPLC on a C 18 Bondapak column (Waters Associates); the gradient conditions were: 10%-40% solvent B over 20 minutes and then 40%-50% solvent B over 20 minutes, followed by a purge with 99% solvent B for 10 minutes (solvent A ϭ .1% trifluoroacetic acid in water and solvent B ϭ .1% trifluoroacetic acid in acetonitrile), at a flow rate of 1 mL/min. Fractions were collected at .3-minute intervals, dried, and analyzed by radioimmunoassay for GLP-2 using the midsequence-directed antiserum, UTTH-7, as previously described. 21 All data are normalized to the peak value of GLP-2 1-33 , corresponding to the elution position of synthetic GLP-2 1-33 .
Data Analysis
All data are expressed as mean Ϯ SE. The median effective concentration (EC 50 ) was calculated using GraphPad Prism software (GraphPad Software, San Diego, CA). Areaunder-the-curve for GLP-2 HPLC peaks was determined using the trapezoidal method. Statistical significance was established by the Student t test or analysis of variance with n-1 custom hypotheses post hoc tests, as appropriate, using SAS (Statistical Analysis Systems, Cary, NC) software. Statistical significance was defined as P Յ .05.
Results
Cloning of the mGLP-2R
To clone the mGLP-2R cDNA, we used a combination of RT-PCR and hybridization screening. Amplification of first-stand mRNA from either mouse jejunum or colon was performed with primers designed to be complementary to the published sequences from the 5= end of the mGLP-2R (GenBank Accession number AF338224) and the 3= end of a published mouse cDNA clone (GenBank NM175681) and yielded a PCR product approximately 1.6 kb in length. Hybridization of a Southern blot with an internal oligonucleotide probe complementary to GLP-2R sequences verified the specificity of the PCR product, as described in the Materials and Methods section. Sequencing and comparison of multiple cDNA clones isolated from preparations of RNA from jejunum and colon yielded identical nucleotide sequences corresponding to a single cDNA (GenBank AY605231) encoding the full-length mGLP-2R (Figure 1) . The cloned mGLP-2R cDNA (GenBank AY605231) differs from a previously published clone, originally isolated as part of a full-length mouse cDNA library (GenBank NM175681), at 4 amino acids (P263H, G459A, V460F, and R485L). Our mGLP-2R amino acid sequence shows 85%-90% identity with the published human and rat GLP-2R sequences, respectively (GenBank AF105367 and AF105368), with highest similarities in the regions encoding the N-terminus, the transmembrane segments, and the distal C-terminus. Functional analysis of the transfected receptor cDNA was performed after subcloning of the mGLP-2R cDNA into an expression vector (pcDNA 3.1). To assess whether GLP-2 3-33 also antagonizes GLP-2 action in a separate independent experimental model, a novel ex vivo murine intestinal muscle strip preparation was developed. RT-PCR analysis confirmed the presence of mRNA transcripts for the GLP-2R in the isolated muscle strips, and addition of h(Gly 2 )GLP-2 stimulated cAMP production, with a maximal response of 234% Ϯ 79% of controls at 10 Ϫ10 mol/L ( Figure 2B, C) . Higher doses of h(Gly 2 )GLP-2 showed reduced cAMP responses, consistent with previous reports. [33] [34] [35] GLP-2 3-33 (10 Ϫ8 mol/L) alone did not stimulate cAMP production (110% Ϯ 11%, of controls, P Ͼ .05) but completely attenuated the stimulatory effect of GLP-2 1-33 (P Ͻ .05) ( Figure  2D ). These experiments strongly suggest that GLP-2 acts as an antagonist on the GLP-2 receptor.
Characterization of the
Body Weight and Small Intestinal Weight in Fasted and Re-fed Mice
Mice fasted for 24 hours exhibited a significant 14% Ϯ 1% decrease in body weight (P Ͻ .001, fasting vs fed) (Table 3) , whereas refeeding for a subsequent 24 hours completely restored weight back to fed levels (P Ͻ .001 vs fasted, P Ͼ .05 vs fed). Small intestinal weight also decreased significantly, by 37% Ϯ 1%, with fasting (P Ͻ .001 vs fed), and fully returned to fed levels with refeeding (P Ͻ .001 vs fasted, P Ͼ .05 vs fed) ( Table 3) . To assess whether these changes in intestinal weight were independent of the changes in body weight, small intestinal weights also were normalized to body weights. Fasting significantly decreased small intestinal weight relative to body weight, by 13% Ϯ 2% (P Ͻ .001 vs fed), and refeeding completely restored relative small intestinal weight (P Ͻ .001 vs fasted, P Ͼ .05 vs fed) ( Figure 3A) .
To investigate the role of endogenous GLP-2 in the adaptive restoration of small intestinal weight, re-fed mice were treated concurrently with rGLP-2 . Lower doses of rGLP-2 3-33 (.3 and 1 ng) did not affect relative small intestinal weight in re-fed mice (data not shown). However, administration of 3 ng of rGLP-2 3-33 significantly abrogated (by 55% Ϯ 20%, P Ͻ .05) the recovery of small intestinal weight with refeeding, whereas 30 ng rGLP-2 3-33 completely (93% Ϯ 27%, P Ͻ .01) prevented intestinal regrowth after refeeding. Furthermore, administration of 3 or 30 ng of rGLP-2 3-33 to control fed mice also resulted in a 12% Ϯ 2% and 9% Ϯ 2% reduction in relative small intestinal weight, respectively (P Ͻ .001 and P Ͻ .01 vs fed) ( Figure 3A) . In contrast to the effects on intestinal weight, treatment with rGLP-2 3-33 had no effect on body weight in either fed or re-fed mice (data not shown).
To determine whether the antagonistic effects of Nterminally truncated GLP-2 peptides are restricted to the specific rat isoform (rGLP-2 3-33 ), we also studied the effects of hGLP-2 3-33 after administration to re-fed mice. Consistent with observations made with rGLP-2 ( Figure 3A ), 3 and 30 ng of hGLP-2 3-33 partially (47% Ϯ 43%, P Ͼ .05) and completely (103% Ϯ 15%, P Ͻ .05) suppressed the restoration of relative small intestinal weight in re-fed mice ( Figure 3B ). Finally, to examine the specificity of the effects of GLP-2 3-33 , several control peptides also were administered to the mice. The N- Figure 1 . Multiple sequence alignment of the mouse, rat, and human GLP-2R amino acid sequences. Alignment was performed with CLUSTAL W 60 (1.82) and rendered with GENEDOC (version 2.6.002). 61 Identity between 2 of the 3 sequences is shown in gray, whereas black shading represents identity across all 3 receptor members. The GenBank accession number for the cloned mouse GLP-2R nucleotide sequence is AY605231.
terminally truncated peptide, GLP-2 5-33 (30 ng), reduced the adaptive regrowth seen in refeeding mice (P Ͻ .05), although the effectiveness of this peptide was less than that with the same dose of GLP-2 3-33 (P Ͻ .001; Figure 3C ). In contrast, neither the structurally related peptide, GLP-1 7-36NH2 (30 ng) nor a molar equivalent dose of rat albumin (660 ng) had any effect on the small intestinal adaptive regrowth.
Food and Water Intake
To ascertain whether the effects of rGLP-2 3-33 on the small intestine of re-fed mice were independent of changes in satiety or thirst, food and water intake were measured in parallel experiments. Control fed mice consumed 4.6 Ϯ .2 g/24 h of chow and re-fed mice consumed 5.9 Ϯ .03 g/24 h of chow (P Ͼ .05). There was no effect of rGLP-2 3-33 on food intake in re-fed mice (P Ͼ .05). Fasting significantly increased water consumption from 5.2 Ϯ .5 mL to 13.7 Ϯ 3.3 mL (P Ͻ .001) and refeeding decreased water consumption back to fed levels (P Ͼ .05 vs fed). rGLP-2 3-33 treatment of refeeding mice did not affect water consumption (P Ͼ .05).
Crypt-Villus Heights
To understand the compartmental changes in the mucosal epithelium associated with fasting and refeeding, we examined jejunal crypt-villus height under different experimental conditions (Figure 4) . Fasting significantly decreased crypt-villus height by 19% Ϯ 2% (P Ͻ .001 vs fed), whereas crypt-villus height was restored to fed levels with refeeding (P Ͻ .001 vs fasted, P Ͼ .05 vs fed). The recovery of crypt-villus height in re-fed mice was reduced significantly by treatment with 3 or 30 ng of GLP-2 , by 25% Ϯ 20% and 32% Ϯ 19%, respectively (both P Ͻ .05 vs re-fed). Furthermore, GLP-2 3-33 also produced an 8% Ϯ 3% reduction in crypt-villus height in control fed mice ( Figure 4D ; P Ͻ .05 vs fed).
Small Intestinal Composition
Intestinal composition was examined to address the potential contributions of water and protein accretion/loss to the weight changes observed in the small intestine. The small intestine of fed mice was composed of 62% Ϯ 1% water and 16% Ϯ 1% protein, and the relative composition was not altered by fasting, refeeding, and/or treatment with rGLP-2 3-33 (data not shown). 
Apoptosis and Proliferation in the Murine Intestine After Fasting and Refeeding
To elucidate the mechanism(s) by which changes in enteral nutrients and endogenous GLP-2 activity affected small intestinal growth, enterocyte proliferation and apoptosis were examined along the crypt-villus axis in the presence or absence of GLP-2 3-33 ( Figure 5 ). Cell proliferation, as assessed by the percentage of Ki-67-immunopositive cells, was observed almost exclusively in the crypts, with the greatest number of cells detected within the rapid proliferating transit zone (cell positions 5-15; Figure 5A-D) . 36 The number of Ki-67-immunopositive cells was not decreased significantly with fasting but was increased significantly in re-fed mice, by 24% Ϯ 3% (P Ͻ .05 vs fasted, P Ͼ .05 vs fed, Figure  5E ). Administration of 3 or 30 ng of GLP-2 3-33 to re-fed mice completely prevented (by 108% Ϯ 25% and 99% Ϯ 9%, respectively) the increase in numbers of Ki-67-immunopositive cells (both P Ͻ .01 vs re-fed), but had no effect on the numbers of immunopositive cells in control fed mice (P Ͼ .05).
Apoptotic TUNEL-positive cells were observed along the entire villus; however, the highest occurrence was observed at the villus tip ( Figure 5F-I) . Villus-tip apoptosis increased by 99% Ϯ 35% with fasting (P Ͻ .05 vs fed), whereas the number of TUNEL-positive cells decreased by 70% Ϯ 7% with refeeding (P Ͻ .05 vs fasted, P Ͼ .05 vs fed, Figure 5J ). Treatment with 3 or 30 ng of GLP-2 3-33 completely (99% Ϯ 21% and 95% Ϯ 23%, respectively) blocked the decrease in numbers of apoptotic cells observed in re-fed mice (both P Ͻ .01 vs re-fed). Furthermore, control fed mice treated with 3 or 30 ng of GLP-2 3-33 also exhibited a 93% Ϯ 22% and 94% Ϯ 35% increase in the number of apoptotic cells in the villus tips, respectively (P Ͻ .05 vs fed).
Small Intestinal Enzymatic Activities After Fasting and Refeeding
To determine the effects of nutrients and rGLP-2 3-33 on small intestinal digestive function, maltase, sucrase, and DP-IV enzymatic activities were examined. The relative activities of these enzymes in control fed mice were 87.6 Ϯ .7, 9.5 Ϯ .1, and 170.3 Ϯ 8.4 U/g of protein, respectively, and these activities did not change with fasting, refeeding, or after administration of GLP-2 3-33 (data not shown).
Proglucagon and GLP-2-Receptor mRNA Transcripts After Fasting and Refeeding
To ascertain whether the major components of the GLP-2-GLP-2R axis were regulated by refeeding and/or rGLP-2 3-33 , mRNA transcript levels for proglucagon and the GLP-2R were determined by semiquantitative RT-PCR using RNA prepared from the ileum and jejunum, respectively ( Figure 6 ). Fasting decreased the levels of proglucagon mRNA transcripts by 72% Ϯ 7% (P Ͻ .01 vs fed), whereas proglucagon mRNA transcripts were increased by 356% Ϯ 94% with refeeding ( Figure 6A ; P Ͻ .001 vs fasted, P Ͼ .05 vs fed). GLP-2 3-33 had no effect on the levels of proglucagon mRNA transcripts. In contrast, fasting and refeeding had no effect on GLP-2R mRNA transcript levels. GLP-2 reduced the levels of GLP-2R mRNA transcripts in control fed mice (by 76% Ϯ 11%, P Ͻ .05 vs fed), but not in fasted/re-fed mice ( Figure 6B ).
Plasma Levels of GLP-2
To assess whether exogenous GLP-2 3-33 modulated plasma levels of endogenous GLP-2 in vivo, rat plasma was assayed for both GLP-2 and GLP-2 after subcutaneous administration of GLP-2 3-33 ( Figure  7 ). Plasma GLP-2 1-33 levels did not change after GLP-2 3-33 injection relative to saline controls (P Ͼ 0.05). Furthermore, although circulating levels of GLP-2 were increased by 550% Ϯ 235% (P Ͻ .05 vs saline controls), the plasma levels of GLP-2 3-33 achieved were similar to those of endogenous GLP-2 . These findings therefore suggest that the biological actions of GLP-2 3-33 on intestinal weight in vivo are not mediated through suppression of endogenous circulating levels of GLP-2 1-33 .
Discussion
Our current understanding of the intestinotropic actions of GLP-2 largely is based on studies in which the peptide was administered exogenously, thereby resulting in supraphysiologic levels of circulating peptide in either normal mice or in mice with pathologic disturbances in gut function. The results of the present study show that endogenous GLP-2 is a physiologic regulator of the intestinotropic response to refeeding in normal mice.
In our current model of gut adaptation, mice that were fasted for 24 hours and then subsequently re-fed for 24 hours showed an acute atrophy of the gut followed by physiologic regrowth back to normal levels, consistent with the results of previous studies. 1,2 By using GLP-2 3-33 as a GLP-2R antagonist, we have now shown that endogenous GLP-2 facilitates this restoration of gut structure in re-fed mice via elongation of the crypt-villus axis. Furthermore, endogenous GLP-2 also was shown to play a role in the maintenance of normal gut structure in control fed mice. These effects were observed using both rat and human GLP-2 3-33 as GLP-2R antagonists, and also were seen to a lesser extent with the shorter fragment GLP-2 5-33 , but not with either GLP-1 7-36NH2 or rat albumin. The reduction in crypt-villus height observed in fasted mice is consistent with the associated reductions in the circulating levels of GLP-2 that occur with the loss of luminal nutrients in the fasted state. 9, 10, 22, 37 These findings also are consistent with the demonstration that administration of GLP-2 prevents the gut atrophy associated with total parenteral nutrition in rats and pigs. 38, 39 Similarly, studies of GLP-2 immunoneutralization in the rat have suggested a role for GLP-2 in the intestinal growth associated with streptozotocininduced, insulin-deficient, hyperphagic diabetes. 40 Our study extends these findings by showing a physiologic role for endogenous GLP-2 in the nutrient-dependent regulation of intestinal growth.
Investigation of the mechanism by which endogenous GLP-2 regulates the growth of the crypt-villus axis showed a clear correlation of GLP-2-mediated changes in small intestinal growth with alterations in both crypt cell proliferation and villus cell apoptosis. Interestingly, GLP-2-stimulated proliferation in re-fed mice was found to occur in the rapidly dividing transit cell region (cells 5-15), a subset of undifferentiated cells believed to be responsible for expansion of the stem cell population that resides immediately below this region. 36 Previous studies showing stimulatory effects of exogenous GLP-2 on crypt-cell proliferation in rodents have not reported on the distribution of the proliferating cells within the crypts. 7, [41] [42] [43] However, Dahly et al 44 found that insulinlike growth factor-1 enhances proliferation in both the mid-(cells [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] and upper-(cells 21-30) crypt in rats on total parenteral nutrition after massive small-bowel resection. In contrast, keratinocyte growth factor stimulates proliferation in cell positions 1-7 in murine crypts, but decreases mitotic labeling in cells at positions 9 -15, 29 while transforming growth factor ␤3 inhibits proliferation in cell positions 3-4 and 13-27. 45 Thus, the actions of GLP-2, at least in re-fed mice, appear to be localized to a distinct region relative to observations made with other intestinal growth factors.
Notably, 24 hours of fasting induced a 2-fold increase in villus apoptosis, and this was reversed by 70% in re-fed mice. Administration of GLP-2 3-33 prevented this reversal. The regulation of apoptosis is well established to be a key mechanism regulating gut growth during fasting and refeeding, 46 -49 and our data suggest that endogenous GLP-2 is a physiologically relevant component of this adaptive process. Several studies have reported on the distribution of apoptotic cells along the villus in response to exogenous GLP-2 administration; however, the majority of these experiments used gut injury models, such as intestinal inflammation, chemotherapy-induced intestinal mucositis, and short-bowel resection with total parenteral nutrition. [12] [13] [14] 42, 50 Consistent with our findings, the incidence of apoptosis in the normal intestine, as detected by the TUNEL assay, appears to be highest at the villus tip. 7, 46, 49 A number of control experiments were performed to ensure that the changes observed in intestinal weight in response to GLP-2 were specific to the effects of GLP-2 on the intestine. GLP-2 3-33 had no effect on food or water intake, and it did not change intestinal composition. A recent study by Tang-Christensen et al 51 showed that GLP-2 can inhibit food intake when injected into the brain of rats. However, peripheral administration of GLP-2 3-33 had no effect on intake of either food or water in the present study, and no changes in body weight were observed. Furthermore, no change in the protein or water composition of the small intestine was found in response to nutritional status or GLP-2 3-33 treatment. Finally, exogenous GLP-2 3-33 did not suppress the circulating levels of GLP-2 . Hence, the available evidence suggests that GLP-2 3-33 exerted its effects via attenuation of the actions of endogenous GLP-2, likely mediated through effects on proliferation and apoptosis, leading to changes in crypt-villus height.
Previous studies using GLP-2 3-33 have shown either no effect, 25, 52 weak agonist activity, 26, 52 or an antagonistic effect 26 of GLP-2 3-33 when co-administered with supraphysiologic levels of GLP-2 or h(Gly 2 )-GLP-2 . These diverse findings are likely a result of differences in the species used (eg, mice and rats), duration of treatment, and the specific doses of GLP-2 administered in the various experiments. Our in vitro studies and a parallel study by Thulesen et al 26 have shown GLP-2 3-33 to be a partial agonist for the GLP-2 receptor at higher concentrations in vitro. Thus, doses of GLP-2 3-33 must be selected carefully to elicit a preferential antagonistic response at the GLP-2 receptor. Hence, studies in which GLP-2 3-33 was shown to exert a partial agonist response used 100-to 1000-fold higher amounts of peptide as compared with the concentrations administered in the present study. 26, 52 Thus, somewhat paradoxically, to antagonize the effects of endogenous GLP-2, low doses of GLP-2 3-33 must be administered. Furthermore, in addition to the present findings with both the BHK-mGLP-R cells and the ex vivo muscle strips, a number of in vitro studies have provided evidence for an antagonistic effect of GLP-2 3-33 on the GLP-2R. Structure-function studies have shown the Nterminus of GLP-2 and amino acids 1-3 in particular are critical for receptor activation but not for receptor binding. 28 Furthermore, receptor-binding studies have shown GLP-2 to possess comparable binding affinity to the full-length ligand GLP-2 . 25, 26 Taken together, these studies suggest that GLP-2 retains the capacity to bind to its receptor but exhibits a reduced capacity for receptor activation owing to truncation of the crucial N-terminal bioactive domain.
Further support for the antagonistic response of the DP-IV metabolite of GLP-2 can be ascertained from parallel studies on hormones of the related glucagon peptide superfamily. 53 The peptides within this family share considerable sequence homology, and many are inactivated by DP-IV cleavage. 54 Furthermore, GLP-1 9 -36amide antagonizes the effects of intact GLP-1 7-36amide both in vitro and in vivo. 55, 56 Moreover, Gault et al 57 showed that the DP-IV metabolite, GIP inhibits the actions of GIP . Hence, N-terminally truncated DP-IV metabolites, including GLP-2 3-33 , commonly display antagonistic properties at their respective cognate receptors.
Sequence analysis of the murine GLP-2R showed 85%-90% amino acid identity with the human and rat GLP-2R, respectively. Previous studies have shown that there is no difference between h(Gly 2 )-GLP-2 and rGLP-2 in their ability to stimulate the GLP-2R, with an EC 50 of .04 -14 nmol/L reported for both peptides with the human and rat GLP-2R. 25, 26, 28, 33, 34, 58 Consistent with these reports, we found an EC 50 of ϳ.4 nmol/L for the mGLP-2R using h(Gly 2 )-GLP-2 . These findings suggest strong similarities in the response of the 3 different (murine, rat, and human) GLP-2 receptors to GLP-2R agonists. The minor variances in responsiveness obtained with the different receptors likely can be explained largely by potential differences in the density of receptor expression in the cell lines used. 59 In summary, the findings of the present study provide evidence for an essential role of GLP-2 in maintaining intestinal structure in the fed state, as well as during adaptation in response to nutrient deprivation and sub-sequent refeeding. Because no model of GLP-2 or GLP-2R deficiency is available, the characterization of GLP-2 3-33 as a GLP-2R antagonist provides a useful experimental reagent by which the physiologic roles of GLP-2 may be explored in other models of intestinal growth or insufficiency.
